Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Clinical trials sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cocktail aims to tackle tough breast cancer Results expected Jun 2027 (estimated)
- New drug cocktail targets tough lung cancer Results expected Aug 2027 (estimated)
- New drug JSKN022 enters human testing for advanced cancers Results expected Aug 2027 (estimated)
-
New hope for advanced cancer patients as experimental drug JSKN021 enters first human tests
Disease control Recruiting nowThis early-stage study tests a new drug, JSKN021, in about 199 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for signs that the drug shrinks tumors…
Phase 1 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for tough breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called JSKN016 against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The goal is to see if JSKN016 can slow cancer growth or extend survival. About 364 adults aged 18 …
Phase 3 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy targets tough lung cancers
Disease control Recruiting nowThis early-stage study tests a new drug combination (JSKN016 plus other treatments) in 288 people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and to check for side effects. Th…
Phase 1 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug JSKN022 enters human testing for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called JSKN022 in 225 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug might …
Phase 1 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug cocktail aims to tackle tough breast cancer
Disease control Recruiting nowThis study tests a new drug called JSKN016, given with chemotherapy or immunotherapy, for people with HER2-negative breast cancer that cannot be removed by surgery or has spread. The trial includes 180 adults in China and aims to see if the combination shrinks tumors and how safe…
Phase 1/2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:35 UTC
-
New hope for Hard-to-Treat breast cancer: JSKN003 enters final trial phase
Disease control Recruiting nowThis study tests a new drug called JSKN003 against standard chemotherapy in 400 people with HER2-low breast cancer that has spread and stopped responding to earlier treatments. Participants are randomly assigned to receive either JSKN003 or a standard chemo drug chosen by their d…
Phase 3 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:22 UTC